LONDON, June 23, 2022 (GLOBE NEWSWIRE) -- Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm. Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.
Male infertility pipeline therapeutics constitutes close to 15 molecules. Out of these approximately 11 molecules are developed by companies and remaining by the universities/institutes.
The Male Infertility Drugs in Development market research report offered by GlobalData Plc provides comprehensive information on the therapeutics under development for male infertility (male health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for male infertility and features dormant and discontinued projects.
Male Infertility Pipeline Products Market Segmentation by Target
- Follicle Stimulating Hormone Receptor
- Telomerase Reverse Transcriptase
- Androgen Receptor
- Non Lysosomal Glucosylceramidase
- Phosphodiesterase 3
- Tumor Necrosis Factor Ligand Superfamily Member 11
Male Infertility Pipeline Products Market Analysis by Target
For more target insights, download a free report sample
Male Infertility Pipeline Products Market Segmentation by Mechanisms of Action
- Follicle Stimulating Hormone Receptor Agonist
- Telomerase Reverse Transcriptase Activator
- Androgen Receptor Agonist
- Non Lysosomal Glucosylceramidase Replacement
- Phosphodiesterase 3 Inhibitor
- Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor
Male Infertility Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Male Infertility Pipeline Products Market Segmentation by Routes of Administration
- Intravenous
- Oral
- Subcutaneous
- Vaginal
Male Infertility Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Male Infertility Pipeline Products Market Segmentation by Molecule Types
- Small Molecule
- Monoclonal Antibody
- Cell Therapy
- Fusion Protein
- Gene Therapy
- Recombinant Enzyme
- Recombinant Protein
Male Infertility Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Leading Companies in the Male Infertility Pipeline Products Market
- Amgen Inc
- Aprilbio Co Ltd
- Beijing FuKangren Bio-pharm Tech Co Ltd
- cStem Regeneration Pharmaceutical Co Ltd
- Ferring Pharmaceuticals Inc
- Igyxos SA
- Neuromagen Pharma Ltd
- Park of Active Molecules
- Prokrea BCN SL
- Reven Holdings Inc
Male Infertility Pipeline Products Market Analysis by Leading Companies
Male Infertility Pipeline Products Market Overview
| Targets | Follicle Stimulating Hormone Receptor, Telomerase Reverse Transcriptase, Androgen Receptor, Non-Lysosomal Glucosylceramidase, Phosphodiesterase 3, and Tumor Necrosis Factor Ligand Superfamily Member 11 |
| Mechanisms of Action | Follicle Stimulating Hormone Receptor Agonist, Telomerase Reverse Transcriptase Activator, Androgen Receptor Agonist, Non-Lysosomal Glucosylceramidase Replacement, Phosphodiesterase 3 Inhibitor, and Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor |
| Routes of Administration | Intravenous, Oral, Subcutaneous, and Vaginal |
| Molecule Types | Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Gene Therapy, Recombinant Enzyme, and Recombinant Protein |
| Leading Companies | Amgen Inc, Aprilbio Co Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, cStem Regeneration Pharmaceutical Co Ltd, Ferring Pharmaceuticals Inc, Igyxos SA, Neuromagen Pharma Ltd, Park of Active Molecules, Prokrea BCN SL, and Reven Holdings Inc |
Male Infertility Pipeline Products Market Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Infertility (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Infertility (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide evaluates Male Infertility (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews key companies involved in Male Infertility (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Male Infertility (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
FAQs
What are the key targets in the male infertility pipeline products market?
The key targets of the male infertility pipeline products market are Follicle Stimulating Hormone Receptor, Telomerase Reverse Transcriptase Androgen Receptor, Non-Lysosomal Glucosylceramidase, Phosphodiesterase 3, and Tumor Necrosis Factor Ligand Superfamily Member 11.
What are the key mechanisms of action in the male infertility pipeline products market?
Some of the key mechanisms of action of the male infertility pipeline products market are Follicle Stimulating Hormone Receptor Agonist, Telomerase Reverse Transcriptase Activator, Androgen Receptor Agonist, Non-Lysosomal Glucosylceramidase Replacement, Phosphodiesterase 3 Inhibitor, and Tumor Necrosis Factor Ligand Superfamily Member 11 Inhibitor.
What are the key routes of administration in the male infertility pipeline products market?
The key routes of administration in the male infertility pipeline products market are intravenous, oral, subcutaneous, and vaginal.
What are the key molecule types in the male infertility pipeline products market?
The key molecule types in the male infertility pipeline products market are small molecule, monoclonal antibody, cell therapy, fusion protein, gene therapy, recombinant enzyme, and recombinant protein.
Which are the leading companies in the male infertility pipeline products market?
Some of the key companies in the male infertility pipeline products market are Amgen Inc, Aprilbio Co Ltd, Beijing FuKangren Bio-pharm Tech Co Ltd, cStem Regeneration Pharmaceutical Co Ltd, Ferring Pharmaceuticals Inc, Igyxos SA, Neuromagen Pharma Ltd, Park of Active Molecules, Prokrea BCN SL, and Reven Holdings Inc.
Related Reports
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
